Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease
Latest Information Update: 23 Sep 2024
At a glance
- Drugs SPK 3006 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms RESOLUTE
- Sponsors Spark Therapeutics
Most Recent Events
- 30 Oct 2023 Time frame changed from 52 weeks to Up to 5 years.
- 30 Oct 2023 Planned End Date changed from 1 Oct 2027 to 1 Apr 2032.
- 30 Oct 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Apr 2032.